MT-101

N/A

Report date: 2023/11/14 20:00:32

Base Information

Drug NameMT-101

Drug Alias NameCD5 ATAK cellsMT-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy > Monocyte cell therapy > Chimeric antigen receptor Monocyte Therapy

Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitors

TargetsT-cell surface glycoprotein CD5

Therapy Area/IndicationsLymphoma, T-Cell, PeripheralMycosis FungoidesLymphoma, T-Cell, Cutaneous

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMyeloid Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMyeloid Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, T-Cell, PeripheralMycosis FungoidesLymphoma, T-Cell, Cutaneous

Other Information

ATC CodeN/A